Whalesbook
Motilal Oswal Ko Kya Lagta Hai?
Motilal Oswal ko lagta hai ki Zydus Wellness ka EBITDA FY26 se FY28 tak 37% per year badhega, RiteBite aur CC segments ko bada karne se. Yeh toh company ki pichli performance se kaafi tagda jump hai.
Valuation Ka Bojh Ya Growth Ka Promise?
Abhi yeh share lagbhag ₹495.65 par hai, aur P/E ratio 77-79x aur EV/EBITDA 49.3x chal raha hai. Iska matlab Zydus Wellness, Dabur India (P/E ~43-44x, EV/EBITDA ~32-36x) aur Britannia Industries (P/E ~54-59x, EV/EBITDA ~36-37x) jaise competitors se kaafi 'expensive' hai. Nestle India ke barabar lagbhag. Motilal Oswal ne FY27 ke liye 23x aur FY28 ke liye 18x valuation predict kiya hai, target price ₹600 rakha hai. Matlab, brokerage ko lagta hai ki future mein valuation kam hoga, par abhi toh share 'mahenga' hai.
Sector Trends Aur Pichli Kahani
Indian FMCG sector mein sab theek chal raha hai, inflation kam hone aur logon ke kharch karne ki aadat wapas aane se FY26 mein revenue 6-8% grow hone ka andaza hai. Healthy snacks jaisi cheezein tezi se chal rahi hain, aur Zydus Wellness ka protein snacks aur nutrition par focus is trend ke hisaab se sahi hai. Par company ka apna financial record dekhein toh pichle 10 saal mein earnings growth sirf 7-8% annual rahi hai. Isliye, brokerage ka yeh forecast ki FY26-28 mein revenue 26% aur EBITDA 37% annual grow hoga, woh achieve karna ek bada challenge hai. Stock bhi last year ₹358.54 se ₹552.40 ke beech mein ghuma hai, aur is saal abhi tak sirf 6.14% bada hai.
Challenges Aur Analyst Ki Chinta
Zydus Wellness ko apne turnaround ke liye kaafi challenges face karne pad rahe hain. Jabki pichle 10 saal mein earnings 7-8% grow hui, ab analysts expect kar rahe hain ki EBITDA growth pakad lega, 20% se zyada domestic aur overall 37% tak. Lekin yeh ambitious target recent results ki wajah se thoda complicated ho gaya hai. Q3 FY26 mein Zydus Wellness ko ₹395 million ka Net Loss hua, mainly higher interest costs aur acquisition ke special expenses ke karan. Comfort Click aur Naturell jaisi acquisitions ko integrate karne ka kaam bhi chal raha hai, jisse aur kharche aa sakte hain ya benefits late ho sakte hain. Company ka market cap ₹15,770 crore ke aas paas hai, par valuation multiples (P/E ~77-79x) abhi bhi Dabur India aur Britannia Industries jaise stable performers ke comparison mein high lagte hain. Bohot saare analysts stock ko 'Buy' keh rahe hain, par average target price ₹512.86 hai, jo short-term mein zyada bada upside nahi dikhata. Kuch analysts ne toh recent mein price targets ko maintain ya kam bhi kiya hai. Company ko stock exchange ko unusual trading volumes par bhi explanations dene pade hain.
Aage Kya?
In risks ke bawajood, zyada tar analysts abhi bhi Zydus Wellness ko 'Strong Buy' recommend kar rahe hain, aur average price targets mein thoda potential gain dikh raha hai. Analysts naye assumptions ke hisaab se price targets revise kar rahe hain, recent changes ek stable ya thoda positive outlook dikha rahe hain. Company ka board May 18, 2026 ko milega March 31, 2026 ko khatam hue financial year ke audited results review karne ke liye, jisse company ke financial path par aur clarity milegi.